We are live on ! Find out more
FGP

Foyston, Gordon, & Payne Portfolio holdings

AUM $468M Turnover 12.5%
1-Year Est. Return 6.67%
This Fund
S&P 500
This Quarter Est. Return
+1.05%
1 Year Est. Return
+6.67%
3 Year Est. Return
+57.25%
5 Year Est. Return
+83.16%
10 Year Est. Return
+253.32%
AUM
$576M
AUM Growth
+$112M
Cap. Flow
+$110M
Cap. Flow %
19.04%
Top 10 Hldgs %
51.94%
Holding
67
New
3
Increased
30
Reduced
21
Closed
4
Avg Time Held
2.7 years
Top 10 Avg Time Held
1.6 years
Top 20 Avg Time Held
1.7 years

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$27.5M
2
UNH icon
UnitedHealth
UNH
+$23.9M
3
MDT icon
Medtronic
MDT
+$13.4M
4
NVS icon
Novartis
NVS
+$6.8M
5
MSFT icon
Microsoft
MSFT
+$6.22M

Top Sells

Rank Stock Value
1
COL
Rockwell Collins
COL
+$12.1M
2
BG icon
Bunge Global
BG
+$3.79M
3
PFE icon
Pfizer
PFE
+$2.92M
4
BHI
Baker Hughes
BHI
+$2.64M
5
JCI icon
Johnson Controls International
JCI
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 36.3%
2 Technology 18.5%
3 Industrials 13.86%
4 Financials 12.79%
5 Consumer Staples 7.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VIV icon
51
Telefônica Brasil
VIV
$20B
$1.36M 0.24%
85,682
-5,800
-6% -$88K
2013 Q3
16 quarters
BDX icon
52
Becton Dickinson
BDX
$52.2B
$1.23M 0.21%
6,458
– –
2013 Q2
17 quarters
SNY icon
53
Sanofi
SNY
$97.3B
$1.19M 0.21%
23,850
– –
2015 Q4
7 quarters
ABBV icon
54
AbbVie
ABBV
$504B
$1.09M 0.19%
12,275
– –
2013 Q2
17 quarters
ABT icon
55
Abbott
ABT
$181B
$685K 0.12%
12,843
– –
2013 Q2
17 quarters
SSL icon
56
Sasol
SSL
$10.5B
$685K 0.12%
24,869
-2,300
-8% -$67.7K
2013 Q3
16 quarters
MMM icon
57
3M
MMM
$85B
$559K 0.1%
3,186
-706
-18% -$122K
2013 Q2
17 quarters
XOM icon
58
ExxonMobil
XOM
$736B
$504K 0.09%
6,145
-1,392
-18% -$111K
2013 Q2
17 quarters
PG icon
59
Procter & Gamble
PG
$370B
$489K 0.08%
5,377
-1,500
-22% -$137K
2013 Q2
17 quarters
CHL
60
DELISTED
China Mobile Limited
CHL
$469K 0.08%
9,283
-700
-7% -$37.3K
2013 Q3
16 quarters
PTR
61
DELISTED
PETROCHINA COMPANY LIMITED ADS (REP 100 H SHARES)
PTR
$454K 0.08%
7,082
-300
-4% -$19K
2013 Q3
16 quarters
IBM icon
62
IBM
IBM
$219B
$241K 0.04%
+1,734
New +$242K
2017 Q3
0 quarters
JPM icon
63
JPMorgan Chase
JPM
$902B
$216K 0.04%
+2,266
New +$209K
2017 Q3
0 quarters
BG icon
64
Bunge Global
BG
$20.4B
– –
-50,806
Closed -$3.79M –
VZ icon
65
Verizon
VZ
$186B
– –
-37,269
Closed -$1.66M –
COL
66
DELISTED
Rockwell Collins
COL
– –
-115,616
Closed -$12.1M –
BHI
67
DELISTED
Baker Hughes
BHI
– –
-48,385
Closed -$2.64M –
1 2
3

Similar funds

GC
Guidance Capital Lousville, Kentucky $468M AUM 26.09% 1-Year Est. Return
SCP
Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return
THC
Truffle Hound Capital Bethesda, Maryland $468M AUM 42.57% 1-Year Est. Return
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $468M AUM 19.67% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $468M AUM 20.53% 1-Year Est. Return
MB
Mizuho Bank Tokyo, Japan $467M AUM 24.01% 1-Year Est. Return
TAM
Talaria Asset Management Melbourne, Australia $467M AUM 14.07% 1-Year Est. Return

Foyston, Gordon, & Payne's Q3 2017 Portfolio in Review

As of Q3 2017, Foyston, Gordon, & Payne held 67 positions worth $576M, up 24% from $464M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Foyston, Gordon, & Payne deployed $110M of net new capital in Q3 2017, opening 3 new positions and adding to 30 existing holdings. Its largest new stake was Baker Hughes: 140,613 shares worth $5.15M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 29% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Pfizer, an estimated $2.92M trimmed.

  • Foyston, Gordon, & Payne's largest Q3 2017 buy was Baker Hughes: 140,613 shares worth $5.15M.
  • Foyston, Gordon, & Payne added most to Johnson & Johnson in Q3 2017, an estimated $27.5M increase.
  • Foyston, Gordon, & Payne's biggest Q3 2017 reduction was Pfizer, cutting an estimated $2.92M.
  • Foyston, Gordon, & Payne fully exited Rockwell Collins in Q3 2017, selling an estimated $12.1M.
  • Foyston, Gordon, & Payne's ten largest holdings make up 52% of its $576M portfolio in Q3 2017.
  • Foyston, Gordon, & Payne opened 3 new positions and closed 4 in Q3 2017.
  • Foyston, Gordon, & Payne's portfolio value rose 24% quarter-over-quarter to $576M.

Based on Foyston, Gordon, & Payne's 13F filing for Q3 2017, filed 14 Nov 2017.